Cervical cancer screening

Leith León-Maldonado; Nancy López-Olmedo; Raúl Murillo; Erika Hurtado-Salgado; Betania Allen-Leigh; Alejandra Armengol-Alonso; Gabriela Torres-Mejía; Sergio Bautista-Arredondo; Tonatiuh Barrientos-Gutiérrez; Eduardo Lazcano-Ponce

doi:10.21149/15894

Cervical cancer screening

Título traducido de la contribución: Tamizaje del cáncer cervical.

Leith León-Maldonado, Nancy López-Olmedo, Raúl Murillo, Erika Hurtado-Salgado, Betania Allen-Leigh, Alejandra Armengol-Alonso, Gabriela Torres-Mejía, Sergio Bautista-Arredondo, Tonatiuh Barrientos-Gutiérrez, Eduardo Lazcano-Ponce

Departamento de Medicina Interna

Producción: Contribución a una revista › Artículo › revisión exhaustiva

1 Cita (Scopus)

Resumen

Objective. To estimate the prevalence of Papanicolaou (Pap) and human papillomavirus (HPV) test use before and after the SARS-CoV-2 pandemic. Materials and methods. We analyzed the use of Pap and/or HPV screening tests by women 25-64 years, using data from the National Health and Nutrition Surveys in 2018 and 2021-2023. Results. Pap use decreased from 34.6% in 2018 to 24.9% in 2021, recovering to 31.5% in 2023. Similarly, HPV use decreased from 12.7% in 2018 to 11% in 2021, increasing to 16.0% in 2023. Greater use of cervical cancer screening was observed at higher socioeconomic levels and urbanization. Conclusions. Improved regulatory guidelines are needed to achieve efficient and effective screening and follow-up of cervical cancer in Mexico.

Título traducido de la contribución	Tamizaje del cáncer cervical.
Idioma original	Inglés
Páginas (desde-hasta)	549-555
Número de páginas	7
Publicación	Salud Publica de Mexico
Volumen	66
N.º	4
DOI	https://doi.org/10.21149/15894
Estado	Publicada - 2024

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.21149/15894

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

@article{5ef2a515340444639265dec34cddc873,

title = "Cervical cancer screening",

abstract = "Objective. To estimate the prevalence of Papanicolaou (Pap) and human papillomavirus (HPV) test use before and after the SARS-CoV-2 pandemic. Materials and methods. We analyzed the use of Pap and/or HPV screening tests by women 25-64 years, using data from the National Health and Nutrition Surveys in 2018 and 2021-2023. Results. Pap use decreased from 34.6% in 2018 to 24.9% in 2021, recovering to 31.5% in 2023. Similarly, HPV use decreased from 12.7% in 2018 to 11% in 2021, increasing to 16.0% in 2023. Greater use of cervical cancer screening was observed at higher socioeconomic levels and urbanization. Conclusions. Improved regulatory guidelines are needed to achieve efficient and effective screening and follow-up of cervical cancer in Mexico.",

keywords = "human papillomavirus DNA tests, papanicolaou, prevalence, screening, uterine cervical neoplasms",

author = "Leith Le{\'o}n-Maldonado and Nancy L{\'o}pez-Olmedo and Ra{\'u}l Murillo and Erika Hurtado-Salgado and Betania Allen-Leigh and Alejandra Armengol-Alonso and Gabriela Torres-Mej{\'i}a and Sergio Bautista-Arredondo and Tonatiuh Barrientos-Guti{\'e}rrez and Eduardo Lazcano-Ponce",

year = "2024",

doi = "10.21149/15894",

language = "English",

volume = "66",

pages = "549--555",

journal = "Salud Publica de Mexico",

issn = "0036-3634",

publisher = "Instituto Nacional de Salud Publica",

number = "4",

}

TY - JOUR

T1 - Cervical cancer screening

AU - León-Maldonado, Leith

AU - López-Olmedo, Nancy

AU - Murillo, Raúl

AU - Hurtado-Salgado, Erika

AU - Allen-Leigh, Betania

AU - Armengol-Alonso, Alejandra

AU - Torres-Mejía, Gabriela

AU - Bautista-Arredondo, Sergio

AU - Barrientos-Gutiérrez, Tonatiuh

AU - Lazcano-Ponce, Eduardo

PY - 2024

Y1 - 2024

N2 - Objective. To estimate the prevalence of Papanicolaou (Pap) and human papillomavirus (HPV) test use before and after the SARS-CoV-2 pandemic. Materials and methods. We analyzed the use of Pap and/or HPV screening tests by women 25-64 years, using data from the National Health and Nutrition Surveys in 2018 and 2021-2023. Results. Pap use decreased from 34.6% in 2018 to 24.9% in 2021, recovering to 31.5% in 2023. Similarly, HPV use decreased from 12.7% in 2018 to 11% in 2021, increasing to 16.0% in 2023. Greater use of cervical cancer screening was observed at higher socioeconomic levels and urbanization. Conclusions. Improved regulatory guidelines are needed to achieve efficient and effective screening and follow-up of cervical cancer in Mexico.

AB - Objective. To estimate the prevalence of Papanicolaou (Pap) and human papillomavirus (HPV) test use before and after the SARS-CoV-2 pandemic. Materials and methods. We analyzed the use of Pap and/or HPV screening tests by women 25-64 years, using data from the National Health and Nutrition Surveys in 2018 and 2021-2023. Results. Pap use decreased from 34.6% in 2018 to 24.9% in 2021, recovering to 31.5% in 2023. Similarly, HPV use decreased from 12.7% in 2018 to 11% in 2021, increasing to 16.0% in 2023. Greater use of cervical cancer screening was observed at higher socioeconomic levels and urbanization. Conclusions. Improved regulatory guidelines are needed to achieve efficient and effective screening and follow-up of cervical cancer in Mexico.

KW - human papillomavirus DNA tests

KW - papanicolaou

KW - prevalence

KW - screening

KW - uterine cervical neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85202775215&partnerID=8YFLogxK

U2 - 10.21149/15894

DO - 10.21149/15894

M3 - Article

AN - SCOPUS:85202775215

SN - 0036-3634

VL - 66

SP - 549

EP - 555

JO - Salud Publica de Mexico

JF - Salud Publica de Mexico

IS - 4

ER -

Cervical cancer screening

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto